We show here that IFN-β/RA combination induces death of tumor cells. To understand the molecular basis for synergistic growth-suppressive action and to identify the gene products that participate in this process, we have employed an antisense knock-out technique. This approach permits the isolation of cell death-associated genes based on their selective inactivation by overexpression of antisense cDNAs. Since the antisense mRNA inactivates gene expression of death specific genes, transfected cells survive in the presence death inducers. Several Genes associated with Retinoid-IFN induced Mortality (GRIM), were identified using this approach.
the pleiotropic biological responses including growth suppression (8) . In mammals, several isotypes for RARs and RXRs exist. Their expression and function are regulated in a tissue and gene specific manner (10). Several studies have shown the importance of these receptors in cell growth regulation (10, 12) . Like IFNs, retinoids induce the expression of a variety of genes (8, 10) . However, it is not clear which gene products inhibit tumor cell proliferation and apoptosis in response to retinoids.
PML-RARα, a mutant retinoic acid receptor found in certain acute promyelocytic leukemias, is generated by gene translocation (13, 14) . Since this receptor responds to RA, it is used as a target for the therapy of APL with RA. Interestingly, this mutant receptor is induced by IFNs and has been reported to participate in the anticellular actions of IFN-α (15) (16) (17) . It forms a nuclear body consisting of several IFN-inducible gene products (18) . We and others have reported earlier that in certain IFN-resistant cells, RA induces STAT1 levels leading to an enhanced IFN-response (19) (20) (21) . These data suggest the existence of a cross talk between IFNand RA-stimulated pathways, although these ligands exert their effects via disparate signaling mechanisms.
Previous studies have shown that the combination of IFN and retinoids is a potent suppressor of cell growth in vitro and in vivo, compared to either agent alone (22, 23) . IFN/RAcombination induces cell death in several breast carcinoma cells. To understand the molecular basis for the cell death and to identify the genes that participate in this process, we have employed a genetic technique, anti-sense technical knock-out (TKO) and identified several novel genes (24) . We have named them GRIM (Genes associated with Retinoid-IFN induced Mortality), based on their function. In this report we describe the isolation and characterization of a novel gene, GRIM-19. It encodes a small, primarily nuclear protein that promotes apoptosis.
MATERIALS & METHODS:
Reagents: Restriction and DNA modifying enzymes (NE Biolabs); G418 Sulfate, IPTG (Life Hygromycin B (Boehringer-Mannheim Inc); and multiple tissue northern blots (Clonetech Inc) were employed in these studies. Human Interferon-β was from Berlex, Inc. Fresh stocks of RA (Sigma) were prepared in ethanol and added to cultures under subdued light.
Cell culture: MCF-7 cells were cultured in phenol red free EMEM supplemented with 5% charcoal stripped fetal bovine serum (CSFBS) and 10 -11 M estradiol during treatment with IFN-β and all trans retinoic acid (RA). Cells were grown in phenol red free media 24h before treatments were initiated. All other cell lines were cultured in media with phenol red but supplemented with 5% CSFBS prior to treatment with IFN-β and RA.
Isolation of GRIM-19 cDNA:
Preparation of an antisense cDNA library using the RNAs derived from untreated and IFN/RA treated BT-20 breast carcinoma cell line, and selection of cells was described earlier (24) . An IFN-stimulated promoter drives the expression of antisense cDNA in the episomal vector,
pTKO1. Briefly, library (40 µg) was electroporated into HeLa cells (10 7 ) and selection was initiated with Hygromycin B (200 µg/ml), human IFN-β (3000 U/ml) and RA (5µM) for 4
weeks. Parallel plates transfected with pTKO1 were selected similarly. Medium was changed and fresh drugs were added daily (first week) and then every other day. At the end of 4 weeks of selection the surviving colonies were pooled, expanded in the presence of hygromycin (200 µg/ml) and Hirt DNA extracts were prepared (25) . DNA was digested with DpnI and electroporated into E. coli DH10B. The resultant colonies were screened by PCR using plasmid specific primers to detect the presence of inserts. Each individual episome was tested for cell protection against IFN/RA induced death in several breast carcinoma cell lines. Individual episomes (10µg) mixed with 30µg of salmon sperm DNA were electroporated into cells. They were then selected with IFN-β (500 U/ml), RA (1µM) and Hygromycin B (100 µg/ml) for 20 days. After that they were grown in media containing Hygromycin B alone. All cells that received pTKO1 vector died by 12 days under these conditions. Episomes that consistently conferred IFN/RA resistance were chosen for sequencing and further characterization.
Caspase assay: To determine the enzymatic activity of caspase-9, a commercially available colorimetric assay kit (Biosource International) was employed. Briefly, cell lysates were prepared after various treatments and a comparable quantity of lysate from each sample was incubated with the synthetic substrate LEHD-pNA. The release of chromophore, pNA (pnitroanilide), from the substrate was quantified by monitoring the absorbance at 405 nm in a microplate reader. Assay was performed as recommended by the manufacturer.
Over expression of GRIM-19 in mammalian cells:
GRIM-19 and its mutant were cloned into pCXN2-myc vector by PCR using primers specific sequence GRIM-19. Restriction sites were added at the 5' and 3' to permit their cloning. The 5'
(forward) primer: 5'-GCGGAATTCGCCACCATGGCGGCGTCAA AGG-3' contains an EcoRI site followed by a Kozak consensus site. The 3' (reverse) primer sequence 5'-GCGGGTACCCGTGTACCACATGAAGCCG-3', contains a KpnI site. The primer used to make the 3' deletion is as follows: GRIM-19∆1 was generated by using a forward primer, described above, and the following reverse primer: 5'-GCGGGTACCCATGATGATG GCCTCCTC-3'. Following PCR, the products were digested with EcoRI and KpnI and subcloned into the mammalian expression vector pCXN2-myc, in which a C-terminal myc-tag is added to the protein (D.J. Lindner and D.V. Kalvakolanu unpublished data). This vector also carries a neomycin selection marker for generating stable cell lines.
Immunoprecipitation:
Cells at 70% confluence in EMEM 5% NCS were treated with human IFN-β (500 U/ml) and RA (1µM) for the indicated times. Plates were then washed extensively with PBS. They were grown in EMEM without methionine and cysteine for additional 2h. 35 S labeled methionine and cysteine (Amersham "ProMix" cat #SJQ0079) was added (50uCi/ml) and incubated at 37 o C for 3h. Cells were lysed in ice-cold RIPA buffer containing protease inhibitors (2.5ug/ml Leupeptin, 10ug/ml Aprotinin, and 0.5mM PMSF). Cell extract (200µg) from each sample was immunoprecipitated using rabbit polyclonal IgG specific for GRIM-19 (1:100 dilution) at 4 o C overnight with gentle rocking. In each case a parallel sample was immunoprecipitated using preimmune IgG from the same rabbit. Protein-G Sepharose (200ul of 1mg/ml stock, Sigma) was added to the immune complexes and incubated with rocking at 4 o C for 3hrs. The bound complexes were centrifuged and the beads were washed 1 time with RIPA buffer then 2 times with wash buffer (0.5M NaCl, 10mM Tris pH 8.0, 0.1% NP40). The final pellet was suspended in loading buffer (30µl) and boiled for 5min before separating on a 12% SDS-polyacrylamdie gel. Gels were fixed in 30% Methanol, 10% Glacial Acetic Acid, and 15% Glycerol for 30 minutes, followed by soaking in a commercially available fluorographic reagent, Amplify (Amersham), dried and fluorographed. Radioactivity in the bands was quantified using a Molecular Dynamics phosphorimager.
Immunofluorescence:
Cells grown in chamber slides (Nalgene) were fixed with 2% paraformaldehyde in PBS for 10 min and then with methanol for 20min at room temperature (26) . The cells were then washed thrice with PBS containing 0.15% glycine, and 0.5% BSA. The cells were then incubated with antibodies specific for GRIM-19 (1:250 dilution) in the same buffer for 1 hour at 37 o C. Cells were washed with PBS and then incubated with Texas red-labeled goat anti-rabbit IgG (1:200 dilution) for 1h. They were then washed with PBS and observed under a fluorescent microscope.
These cells were also counter stained with DAPI (0.2µg/ml) to visualize the nuclei. In certain experiments the primary antibody was pre-incubated with bacterially expressed GRIM-19 (5µg) for 1hr before using in the experiment.
RESULTS:
Induction of cell death by the IFN/RA combination in breast carcinoma cells:
IFNs have been shown to be less effective in the therapy of solid tumor cell growth, compared to hematologic tumors such as chronic myelogenous leukemia (27, 28) . To determine whether RA would enhance the growth suppression, we treated MCF-7 cells with IFN−β, RA, or IFN-β/RA for various days and measured cell death using the Sulforhodamine B (SRB) binding assay (29) .
As shown in Figure1A, either IFN-β (250U/ml) or RA (1µM) alone marginally suppressed the growth, but did not induce death of MCF-7 cells. In contrast, the combination of IFN/RA caused a time-dependent increase in cell death. By 10-12 days all the cells in the culture were killed by IFN/RA combination. Annexin-V binding assays were conducted to determine whether the cell death was similar to apoptosis ( Figure 1B To further prove the growth promoting effects of antisense GRIM-19, two HeLa cell lines, which expressed the pTKO1 vector alone or the GRIM-19 in an antisense orientation were prepared. These cells were exposed to the combination of IFN-β (1500U/ml) and retinoic acid (2µM) for several days and the growth was monitored using the SRB assay. Antisense GRIM-19
was capable of conferring a strong growth advantage to cells as detected by an increase in the absorbance ( Figure 2B ). The vector-transfected cells failed to grow under these conditions. Northern blot analyses identified a single mRNA species (see below).
Expression and generation of antibodies specific to GRIM-19 protein:
The was analyzed by SDS-PAGE followed by silver staining analysis ( Figure 4B ). The purified protein, after removal of expression tag, was used for raising antibodies in rabbits. These antibodies were used for western blot analysis. As shown in Figure 4D , these antibodies specifically detected GRIM-19 but not the Tag protein. Pre-immune sera did not detect any protein ( Figure 4C ).
Inhibition of GRIM-19 gene expression by antisense cDNA:
To provide a direct evidence for the repression of GRIM-19 protein by antisense, northern blot analyses were performed. These assays were performed using the RNA derived from HeLa and MCF-7 cells. For conducting these experiments, a control cell line was generated by transfecting the pTKO1 vector and selecting the cells with Hygromycin-B. Stable cell lines were treated for 3 days with IFN-β (500U/ml) and RA (1µM), RNA was extracted, and northern blots were prepared. These blots were probed with a 32 P-labeled GRIM-19 cDNA. As anticipated the vector transfected HeLa cells expressed a fast moving RNA of about 550bp (marked as E in Figure 5A ). In contrast, a fast and a slow moving band were detected in cells transfected with from the endogenous and transfected genes, respectively. Similar data was obtained from MCF-7 cells ( Figure 5C ).
We next determined whether antisense expression caused a reduction in the levels of endogenous GRIM-19 protein. Cell extracts were prepared and equal amounts of cell extracts were used in western blots. These blots were probed with antibodies described in Figure 4D .
While a normal expression of the GRIM-19 protein was seen in the vector-transfected cells, it was completely repressed in cells transfected with the antisense-GRIM-19 episome ( Figure 5B and 5D). A parallel blot containing the same extracts was probed with a monoclonal antibody raised against IFN-regulated RNAseL. The levels of RNAseL, however, were unchanged in both the cases ( Figure 5E ). 
Induction of GRIM-

Tissue distribution of GRIM-19 mRNA:
To provide further evidence that the GRIM-19 cDNA was not a cloning artifact, we probed commercially available northern blots containing poly A + RNA from multiple human tissues (Clonetech Inc). Although the GRIM-19 is detectable in a wide variety of human tissues, a tissue-specific variation is observed ( Figure 3A) . Notably, the human heart, skeletal muscle, liver and kidney and placenta expressed higher steady state levels of GRIM-19, relative to other tissues. Human Lung, peripheral blood leukocytes, spleen and thymus and colon had the lowest GRIM-19 expression These blots were also probed with β-actin to ensure the presence of comparable amount of RNA in all the tracks ( Figure 7B ). Consistent with the reports of the presence of two different forms of actin in human cardiac and skeletal muscles, these can be readily detected in those tissues but not in others. In the cells of human hematopoietic system, GRIM-19 is present in variable amounts. In fetal liver, spleen, and bone marrow highest level of GRIM-19 was observed ( Figure 7C ).
Overexpression of GRIM-19 enhances cell death:
Since 
Deletion of the C-terminus of GRIM-19 inhibits its death promoting function:
To define the functional domain(s) of GRIM-19 important for its death regulatory actions, a mutant lacking the C-terminus (GRIM-19∆1) was generated. This mutant was arbitrarily designed, by removing the C-terminal 43 amino acids and was expressed as a mycepitope tagged fusion protein in MCF-7 cells ( Figure 10A) . Effect of the mutant on IFN/RA- 
DISCUSSION:
Given the multitude of ISGs and RA-responsive genes it has been difficult to precisely To identify the GRIMs, we have employed an antisense knock-out method, which permits the isolation of death-associated genes by a functional inactivation (30) . Our preliminary sequence analyses suggest that GRIMs do not include any of the known death-activating genes (24) . This observation suggests several possibilities. First, the previously described death activators do not regulate IFN/RA induced apoptosis. Second, they cannot be inactivated by antisense approaches. Third, such gene products are at the terminal phase of death pathway and their inactivation is insufficient to overcome the death. The rescue of multiple GRIMs in our studies suggests that the IFN/RA-combination uses a death pathway consisting of several steps.
It is likely these GRIMs constitute a single linear pathway with multiple branch points or multiple parallel pathways that converge at various points. Consequently inactivation of a single GRIM is sufficient to suppress cell death. One of the GRIMs is a redox-regulatory enzyme, thioredoxin reductase (GRIM-12) (24) . In this study we described GRIM- The presence of GRIM-19 mRNA in normal tissues suggests that it is not a cloning artifact. Surprisingly, some tissues such as heart, skeletal muscle and kidney express a high steady state level of GRIM-19 mRNA. Such expression may not mean that these tissues undergo apoptosis spontaneously. It is important to emphasize that GRIM-19 interacts with other proteins and undergoes phosphorylation (figure 6E and data not shown). This would suggest that its activity is regulated by other factors. Therefore, in the absence of exogenous cues it may not activate death. Indeed, the IFN/RA combination requires multiple gene products to execute cell death as suggested by the rescue of multiple GRIMs (24) . Thus, a concerted action of these products is critical for mediating cell death. Therefore, higher expression of a single GRIM is insufficient to induce death. However, consistent with its role in death pathways, overexpression of GRIM-19 enhances the cellular sensitivity to IFN/RA induced death (Figures 8 and 9 ). Interestingly, truncated protein can be expressed in higher amounts than the wild type protein ( Figure 9A ) in several experiments. This difference could be due to a lesser cytotoxicity of the mutant protein, compared to the wild type.
Nucleotide binding proteins, in particular to those that bind to GTP seem to play specific roles in the IFN actions. Some of these, such as the Mx (44) (44, 46) . Contrary to these, GRIM-19 is a small, predominantly nuclear protein ( Figure 11 ).
We speculate that it may aid in functions such as importing of death activating proteins into the nucleus. Its activity may be regulated protein kinases in response to exogenous death cues.
Preliminary studies indicate that GRIM-19 protein is constitutively phosphorylated and IFN/RA combination hyperinduces it (data not presented). A small amount of this protein is also in the cytoplasm. Therefore, it may mediate other death related functions in the cytoplasm.
Immunofluorescence analysis with the available polyclonal antibodies revealed no obvious 
